DE69228938D1 - Methode und zusammensetzungen zur behandlung von zerebralparalyse - Google Patents
Methode und zusammensetzungen zur behandlung von zerebralparalyseInfo
- Publication number
- DE69228938D1 DE69228938D1 DE69228938T DE69228938T DE69228938D1 DE 69228938 D1 DE69228938 D1 DE 69228938D1 DE 69228938 T DE69228938 T DE 69228938T DE 69228938 T DE69228938 T DE 69228938T DE 69228938 D1 DE69228938 D1 DE 69228938D1
- Authority
- DE
- Germany
- Prior art keywords
- compositions
- treating cerebral
- cerebral paralysis
- paralysis
- botulinum toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919120306A GB9120306D0 (en) | 1991-09-24 | 1991-09-24 | Method and compositions for the treatment of cerebral palsy |
GB9120306 | 1991-09-24 | ||
PCT/GB1992/001697 WO1993005800A1 (en) | 1991-09-24 | 1992-09-16 | Method and compositions for the treatment of cerebral palsy |
Publications (3)
Publication Number | Publication Date |
---|---|
DE69228938D1 true DE69228938D1 (de) | 1999-05-20 |
DE69228938T2 DE69228938T2 (de) | 1999-09-23 |
DE69228938T3 DE69228938T3 (de) | 2008-01-03 |
Family
ID=10701881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69228938T Expired - Lifetime DE69228938T3 (de) | 1991-09-24 | 1992-09-16 | Verwendung von präsynaptischen Neurotoxin zur Behandlung von Zerebralparalyse |
Country Status (13)
Country | Link |
---|---|
US (7) | US6395277B1 (de) |
EP (1) | EP0605501B2 (de) |
JP (2) | JP3535872B2 (de) |
AT (1) | ATE178799T1 (de) |
AU (1) | AU666334B2 (de) |
CA (1) | CA2119562C (de) |
DE (1) | DE69228938T3 (de) |
DK (1) | DK0605501T5 (de) |
ES (1) | ES2131073T5 (de) |
GB (1) | GB9120306D0 (de) |
GR (1) | GR3030418T3 (de) |
NO (2) | NO312747B1 (de) |
WO (1) | WO1993005800A1 (de) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5919665A (en) | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
US7384918B2 (en) * | 1991-09-24 | 2008-06-10 | Allergan, Inc. | Botulinum toxin for treating muscle contracture |
GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US6939852B2 (en) * | 1991-09-24 | 2005-09-06 | Allergan, Inc. | Methods and compositions for the treatment of cerebral palsy |
JP3510886B2 (ja) * | 1992-06-23 | 2004-03-29 | ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド | ボツリヌスb複合体を含有する医薬組成物 |
EP1099445A3 (de) * | 1993-06-10 | 2001-09-05 | Allergan, Inc. | Behandlung neuromuskulärer Erkrankungen und Zuständen mit unterschiedlichen Botulinum Serotypen |
EP0702559B1 (de) * | 1993-06-10 | 2003-03-19 | Allergan, Inc. | Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US20040126396A1 (en) * | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
US8187612B2 (en) * | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
EP1147776B1 (de) * | 1993-12-28 | 2010-12-15 | Allergan, Inc. | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen |
US8557256B2 (en) * | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
AU2007202480B2 (en) * | 1993-12-28 | 2009-01-29 | Allergan, Inc. | Method for treating pain associated with a muscle disorder |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
US5670484A (en) * | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
JP3066079B2 (ja) * | 1994-05-09 | 2000-07-17 | ビンダー,ウィリアム,ジェイ. | 頭痛を低減する方法 |
BR9509903A (pt) * | 1994-10-24 | 1997-11-25 | Ophidian Pharm Inc | Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial |
JP2002501033A (ja) | 1998-01-26 | 2002-01-15 | ユニバーシティー オブ マサチューセッツ | A型ボツリヌス菌の生物学的活性赤血球凝集素とその使用法 |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
US6337075B1 (en) * | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US7494661B2 (en) * | 2000-06-28 | 2009-02-24 | Ira Sanders | Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
ES2617692T3 (es) * | 2000-07-21 | 2017-06-19 | Revance Therapeutics, Inc. | Sistemas de transporte de agentes biológicos de múltiples componentes |
US20040219619A1 (en) * | 2000-07-21 | 2004-11-04 | Ester Fernandez-Salas | Methods of identifying compounds that alter toxin persistence and/or protease activity |
US7491799B2 (en) * | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US7691983B2 (en) * | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Chimera botulinum toxin type E |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
ITUD20010002A1 (it) * | 2001-01-05 | 2002-07-05 | Univ Degli Studi Udine | Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo |
JP4707254B2 (ja) * | 2001-04-24 | 2011-06-22 | クミアイ化学工業株式会社 | 粒状組成物及びその製造方法 |
NZ533309A (en) | 2001-11-15 | 2006-03-31 | Micro Algae Corp | Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US20050163809A1 (en) * | 2002-03-29 | 2005-07-28 | Ryuji Kaji | Remedy for hypermyotonia |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
US6776991B2 (en) | 2002-06-26 | 2004-08-17 | Allergan, Inc. | Methods for treating priapism |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
KR20050094817A (ko) * | 2002-12-20 | 2005-09-28 | 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. | 개선된 약제학적 보툴리늄 독소 조성물 |
MXPA05009425A (es) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica. |
US7393538B2 (en) * | 2003-04-25 | 2008-07-01 | Ackerman Alan H | Clostridial toxin treatment for dermatillomania |
US7390496B2 (en) * | 2003-04-25 | 2008-06-24 | Allergan, Inc. | Therapeutic treatments for repetitive hand washing |
US7396535B2 (en) * | 2003-04-25 | 2008-07-08 | Ackerman Alan H | Therapy for obsessive compulsive head banging |
US7422753B2 (en) * | 2003-04-25 | 2008-09-09 | Allergan, Inc. | Methods for treating trichotillomania |
US7393537B2 (en) * | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
US20050013850A1 (en) * | 2003-07-15 | 2005-01-20 | Caers Jan K. | Device to assist hyperhydrosis therapy |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
US20050148935A1 (en) * | 2003-12-29 | 2005-07-07 | Rozalina Dimitrova | Botulinum toxin injection guide |
CA2558676C (en) * | 2004-03-03 | 2019-04-16 | Essentia Biosystems, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
TR201815364T4 (tr) | 2004-03-03 | 2018-11-21 | Revance Therapeutics Inc | Botulinum toksinlerinin topikal uygulaması ve transdermal dağıtımı. |
US20050206225A1 (en) * | 2004-03-18 | 2005-09-22 | Ford Global Technologies, Llc | Method and apparatus for predicting the position of a trailer relative to a vehicle |
AU2005244096B2 (en) * | 2004-05-07 | 2011-03-17 | Algenis Spa | Transdermal administration of phycotoxins |
BRPI0510759A (pt) * | 2004-05-07 | 2007-11-20 | Phytotox Ltd | método de facilitar a cura de um ferimento |
US20080045889A1 (en) * | 2004-07-21 | 2008-02-21 | Gerondale Scott J | Botoxo Needle Injector |
US20060024794A1 (en) * | 2004-07-30 | 2006-02-02 | Shengwen Li | Novel methods for production of di-chain botulinum toxin |
US8022179B2 (en) * | 2005-03-03 | 2011-09-20 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
WO2006094263A2 (en) * | 2005-03-03 | 2006-09-08 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
AU2006346369B2 (en) * | 2005-07-18 | 2013-02-21 | University Of Massachusetts Lowell | Compositions and methods for making and using nanoemulsions |
EP1906923B1 (de) | 2005-07-22 | 2018-01-24 | The Foundry, LLC | Systeme und verfahren zur freisetzung eines therapeutischen wirkstoffes |
US7655243B2 (en) * | 2005-07-22 | 2010-02-02 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US10052465B2 (en) | 2005-07-22 | 2018-08-21 | The Foundry, Llc | Methods and systems for toxin delivery to the nasal cavity |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US7910116B2 (en) * | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
CN101355962A (zh) * | 2005-11-17 | 2009-01-28 | 雷文斯治疗公司 | 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法 |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
WO2008045107A2 (en) | 2005-12-01 | 2008-04-17 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US7794386B2 (en) | 2006-03-15 | 2010-09-14 | Allergan, Inc. | Methods for facilitating weight loss |
US7811586B2 (en) | 2006-05-02 | 2010-10-12 | Allergan, Inc. | Methods for alleviating testicular pain |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
US20080092910A1 (en) * | 2006-10-18 | 2008-04-24 | Allergan, Inc. | Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures |
US20080113051A1 (en) * | 2006-11-13 | 2008-05-15 | Allergan, Inc. | Methods for alleviating tattoo pain |
US20100172943A1 (en) | 2006-12-01 | 2010-07-08 | Anterios, Inc. | Peptide nanoparticles and uses therefor |
CA2671447A1 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Amphiphilic entity nanoparticles |
NZ598039A (en) * | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
NZ598159A (en) * | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Transport molecules using reverse sequence hiv-tat polypeptides |
CN101765423B (zh) | 2007-05-31 | 2014-08-06 | 安特里奥公司 | 核酸纳米粒子和其用途 |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
EP2662046B1 (de) | 2008-05-09 | 2023-03-15 | Nuvaira, Inc. | Systeme und Baugruppen zur Behandlung eines Bronchialbaumes |
CN105147608B (zh) * | 2008-06-26 | 2019-12-10 | 安特里奥公司 | 真皮递送 |
CN102149398B (zh) | 2008-09-11 | 2013-12-04 | I·B·R·以色列生物科技研究有限公司 | 雪片莲属鳞茎提取物及其用途 |
US8506970B2 (en) * | 2008-10-14 | 2013-08-13 | Dt Scimed, Llc | Dose and localization of botulinum toxins in skin and muscle |
JP4697289B2 (ja) | 2008-11-05 | 2011-06-08 | ソニー株式会社 | 撮像装置、撮像装置の表示制御方法 |
US20100124559A1 (en) * | 2008-11-20 | 2010-05-20 | Allergan, Inc. | Early Treatment and Prevention of Increased Muscle Tonicity |
EP2364168A1 (de) | 2008-12-04 | 2011-09-14 | Botulinum Toxin Research Associates, Inc. | Verlängerte botulinustoxin-formulierung zur anwendung bei menschen oder säugetieren |
US8147848B2 (en) | 2009-08-26 | 2012-04-03 | Allergan, Inc. | Method for treating premature ejaculation with a botulinum neurotoxin |
CN107049479B (zh) | 2009-10-27 | 2020-10-16 | 努瓦拉公司 | 具有可冷却的能量发射组件的递送装置 |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
KR101820542B1 (ko) | 2009-11-11 | 2018-01-19 | 호라이라 인코포레이티드 | 조직을 치료하고 협착을 제어하기 위한 방법, 기구 및 장치 |
EP2729163A1 (de) | 2011-07-08 | 2014-05-14 | Allergan, Inc. | Verfahren zur behandlung von autonomen nervensystemerkrankungen |
US8992941B2 (en) | 2011-07-08 | 2015-03-31 | Allergan, Inc. | Method for treatment of esophageal spasm |
KR20140054055A (ko) | 2011-07-14 | 2014-05-08 | 알러간, 인코포레이티드 | 성행위와 관련된 실금의 치료방법 |
MX2014000612A (es) | 2011-07-20 | 2014-02-27 | Allergan Inc | Toxinas botulinicas para usar en un metodo para el tratamiento de depositos adiposos. |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
WO2014048740A1 (en) | 2012-09-25 | 2014-04-03 | Haldor Topsøe A/S | Steam reforming catalyst and method of making thereof |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
JP6930969B2 (ja) | 2015-07-08 | 2021-09-01 | ギルローズ ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
CN110198703A (zh) | 2016-11-21 | 2019-09-03 | 艾里奥治疗公司 | 大试剂的透皮递送 |
US20210361683A1 (en) * | 2018-05-24 | 2021-11-25 | Children's Hospital Medical Center | Compositions and methods for the treatment of muscle contractures |
US20230365957A1 (en) * | 2020-10-07 | 2023-11-16 | Pro-Tox Inc. | Vacuum drying method for botulinum toxin |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2373454A (en) * | 1943-07-09 | 1945-04-10 | Squibb & Sons Inc | Method of preparing tetanus toxin |
US2719102A (en) * | 1949-10-28 | 1955-09-27 | Corn States Serum Company | Clostridium perfringens toxoid and process of making the same |
US3132995A (en) * | 1961-10-20 | 1964-05-12 | Carter Prod Inc | Endotoxin fractions and method for producing same |
US4234566A (en) * | 1979-06-29 | 1980-11-18 | Packman Elias W | Antihistamine and methods for use thereof |
US4720494A (en) * | 1984-11-05 | 1988-01-19 | The Gillette Company | Anticholinergic eucatropine esters and antiperspirant use thereof |
US4713240A (en) * | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
EP0262396A3 (de) | 1986-09-20 | 1989-08-23 | Heinz Dipl.-Ing. Hölter | Verfahren zum Herstellen von Calciumsulfatdihydrat bei der Rauchgasentschwefelung |
US5055291A (en) * | 1986-11-04 | 1991-10-08 | Baylor College Of Medicine | Compositions for preventing secondary cataracts |
US4935969A (en) * | 1987-12-02 | 1990-06-26 | Farnsworth Orin J | Method and device for the controlled disposal of human waste |
US4932936A (en) * | 1988-01-29 | 1990-06-12 | Regents Of The University Of Minnesota | Method and device for pharmacological control of spasticity |
US5053005A (en) * | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
US5056291A (en) * | 1989-10-19 | 1991-10-15 | Skilland Engineering, Ltd. | Modular system for space frame structures |
US5055302A (en) * | 1990-02-22 | 1991-10-08 | Trustees Of The University Of Pennsylvania | Neuropeptide control of ocular growth |
US5183462A (en) * | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
US5401243A (en) * | 1990-08-21 | 1995-03-28 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
US7384918B2 (en) * | 1991-09-24 | 2008-06-10 | Allergan, Inc. | Botulinum toxin for treating muscle contracture |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US6939852B2 (en) * | 1991-09-24 | 2005-09-06 | Allergan, Inc. | Methods and compositions for the treatment of cerebral palsy |
FR2692475B1 (fr) | 1992-06-19 | 2000-04-21 | Montpellier Chirurgie | Prothese totale du genou. |
JP3510886B2 (ja) | 1992-06-23 | 2004-03-29 | ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド | ボツリヌスb複合体を含有する医薬組成物 |
JPH06192296A (ja) | 1992-10-28 | 1994-07-12 | Chiba Pref Gov | 治療用医薬品としての結晶a型ボツリヌス毒素の製造法。 |
EP0679090A1 (de) | 1993-01-15 | 1995-11-02 | Interactive Biologics Associates | Verfahren zur behandlung von gesichtsmuskel schmez syndrom |
US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
EP0702559B1 (de) | 1993-06-10 | 2003-03-19 | Allergan, Inc. | Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen |
EP1099445A3 (de) | 1993-06-10 | 2001-09-05 | Allergan, Inc. | Behandlung neuromuskulärer Erkrankungen und Zuständen mit unterschiedlichen Botulinum Serotypen |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US8187612B2 (en) * | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
EP1147776B1 (de) | 1993-12-28 | 2010-12-15 | Allergan, Inc. | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen |
US8557256B2 (en) * | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
US6986893B2 (en) * | 1993-12-28 | 2006-01-17 | Allergan, Inc. | Method for treating a mucus secretion |
US20040126396A1 (en) * | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
US5766605A (en) | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
JP3066079B2 (ja) | 1994-05-09 | 2000-07-17 | ビンダー,ウィリアム,ジェイ. | 頭痛を低減する方法 |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US6113915A (en) * | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6500436B2 (en) * | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US6623742B2 (en) * | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
TWI243265B (en) | 2002-02-27 | 2005-11-11 | Chi Mei Optoelectronics Corp | Method for forming a reflection-type light diffuser |
-
1991
- 1991-09-24 GB GB919120306A patent/GB9120306D0/en active Pending
-
1992
- 1992-09-16 JP JP50589693A patent/JP3535872B2/ja not_active Expired - Lifetime
- 1992-09-16 AU AU25664/92A patent/AU666334B2/en not_active Expired
- 1992-09-16 CA CA002119562A patent/CA2119562C/en not_active Expired - Lifetime
- 1992-09-16 ES ES92919570T patent/ES2131073T5/es not_active Expired - Lifetime
- 1992-09-16 DK DK92919570T patent/DK0605501T5/da active
- 1992-09-16 WO PCT/GB1992/001697 patent/WO1993005800A1/en active IP Right Grant
- 1992-09-16 EP EP92919570A patent/EP0605501B2/de not_active Expired - Lifetime
- 1992-09-16 DE DE69228938T patent/DE69228938T3/de not_active Expired - Lifetime
- 1992-09-16 AT AT92919570T patent/ATE178799T1/de active
- 1992-09-16 US US08/211,352 patent/US6395277B1/en not_active Expired - Fee Related
-
1994
- 1994-03-23 NO NO19941065A patent/NO312747B1/no not_active IP Right Cessation
-
1999
- 1999-06-03 GR GR990401502T patent/GR3030418T3/el unknown
-
2001
- 2001-07-06 JP JP2001206187A patent/JP2002097154A/ja active Pending
- 2001-07-06 US US09/900,380 patent/US6448231B2/en not_active Expired - Lifetime
- 2001-07-30 NO NO20013727A patent/NO324159B1/no not_active IP Right Cessation
-
2002
- 2002-05-22 US US10/155,280 patent/US20020142010A1/en not_active Abandoned
-
2004
- 2004-10-29 US US10/976,507 patent/US20050112146A1/en not_active Abandoned
- 2004-10-29 US US10/976,690 patent/US20050142150A1/en not_active Abandoned
-
2007
- 2007-05-22 US US11/752,096 patent/US7378389B2/en not_active Expired - Fee Related
-
2008
- 2008-04-29 US US12/111,904 patent/US20080206224A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69228938D1 (de) | Methode und zusammensetzungen zur behandlung von zerebralparalyse | |
ATE477816T1 (de) | Botulinum toxin zur behandlung von akuten verletzungen der skelettmuskeln | |
UA26213C2 (uk) | Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові | |
DE69435321D1 (de) | Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms | |
DE69733132D1 (de) | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen | |
DE69805202T2 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
DE69731540D1 (de) | Behandlung von diarrhoe | |
ATE154758T1 (de) | Levobupivacain nützlich zur behandlung von chronischen schmerzen | |
ATE222488T1 (de) | Verwendung von anti-vegf-mitteln zur behandlung der endometriose | |
ATE198706T1 (de) | Polyamin-verbindungen zur behandlung von proliferativer erkrankungen | |
ATE110958T1 (de) | Verwendung von sertralin zur behandlung verfrühter ejakulation. | |
UA35567C2 (uk) | Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату | |
DK71387D0 (da) | Terapeutisk middel til behandling af psoriasis | |
BR9500436A (pt) | Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico | |
DE69429856D1 (de) | Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit | |
ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
DE68919673T2 (de) | Verfahren zur behandlung und vorbeugung des verlustes von knochenmasse. | |
DE69424679D1 (de) | Zusammensetzung zur behandlung oder vorbeugung von herpes | |
ATE295731T1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
DE3585312D1 (de) | Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden. | |
DE69022027T2 (de) | 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia. | |
UA41153A (uk) | Спосіб немедикаментозного лікування симпато-адреналових пароксизмів |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8366 | Restricted maintained after opposition proceedings | ||
8332 | No legal effect for de | ||
R071 | Expiry of right |
Ref document number: 605501 Country of ref document: EP |